WO2007125147A1 - Composition à base d'isoprénaline, de noradrénaline et d'adrénaline - Google Patents

Composition à base d'isoprénaline, de noradrénaline et d'adrénaline Download PDF

Info

Publication number
WO2007125147A1
WO2007125147A1 PCT/ES2007/000262 ES2007000262W WO2007125147A1 WO 2007125147 A1 WO2007125147 A1 WO 2007125147A1 ES 2007000262 W ES2007000262 W ES 2007000262W WO 2007125147 A1 WO2007125147 A1 WO 2007125147A1
Authority
WO
WIPO (PCT)
Prior art keywords
isoprenaline
adrenaline
composition
man
noradrenaline
Prior art date
Application number
PCT/ES2007/000262
Other languages
English (en)
Spanish (es)
Inventor
Luis GARCÍA AUGIER
Original Assignee
Garcia Augier Luis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garcia Augier Luis filed Critical Garcia Augier Luis
Publication of WO2007125147A1 publication Critical patent/WO2007125147A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Definitions

  • composition based on isoprenaline, norepinephrine and adrenaline Composition based on isoprenaline, norepinephrine and adrenaline
  • Isoprenaline molecule is specific in its vasodilator action when activating beta receptors.
  • Noradrenaline molecule The known effect of the Noradrenaline molecule is of a vasoconstriction due to its specific action on alpha receptors.
  • Adrenaline molecule The known use of the Adrenaline molecule is that at low concentrations it is vasodilator when acting on beta receptors, and at high concentrations it is vasoconstrictor when acting on alpha receptors.
  • Isoprenaline a substance that demonstrated its human endogenous generation, by using a "buccal inter-dental device regulating proton and / or electronic flow". This gave reason to Ia presentation of the patent application CL2896-1998, on November 30, 1998, of the same owner, who did not prosper because the protocol of action of Isoprenaline at that time was too preliminary.
  • Isoprenaline is used in severe asthmatic cases at levels of 2 to 4 ug / kg / min. In its novel use the concentrations range from 6x10 (-4) to 6x10 (-9) grams of Isoprenaline per day.
  • Adrenaline in the prior art is used in concentrations of 1 mg / mL. The novel use ranges from 5x10 (-5) to 5x10 (-9) mg of Adrenaline per day.
  • Noradrenaline in the prior art does not have a great therapeutic use.
  • the novel use of Noradrenaline ranges from 5x10 (-5) to 5x10 (-9) mg per day.
  • Isoprenaline causes the destruction of the 7 neutrons of the atomic nucleus of Nitrogen and the release of 7 hydrogens. The 7 released protons that are incorporated into the cellular respiration are occupied, coupling to the 7OH forming 7 water molecules.
  • Noradrenaline causes the destruction of the 8 neutrons in the Oxygen nucleus, releasing 8 Hydrogens. The 8 protons and electrons enter the cellular respiration chain.
  • Adrenaline causes cold hydrogen fusion by adding protons and electrons from cellular respiration, and is responsible for the growth of Living Beings. The purpose of the Cellular Respiration is the ionic balance. Where it is observed that the sum of protons and electrons of Nitrogen 7 + 1 equals 8 of the Oxygen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Tout comme les êtres vivants, l'environnement et l'être humain ont besoin de l'apport énergétique fourni par l'atmosphère et la terre pour que puisse se développer le phénomène complémentaire de la vie. L'être humain n'a accès qu'à 22% de l'atmosphère contenant l'oxygène comme source énergétique terrestre. L'isoprénaline, une molécule de formation endogène chez l'être humain moyennant un processus biotechnologique, réalise la rupture des sept neutrons de l'azote et contient 78% de cette atmosphère manquant à cette diète complémentaire. Il est important de souligner que dans la diète actuelle disponible pour les être vivants, l'environnement et l'être humain, les protides, glucides et lipides sont insuffisants par le développement de ce phénomène complémentaire de la vie. La présente invention concerne la fission à froid de l'oxygène, la fusion à froid de l'hydrogène et la fission à froid de l'azote qui se produisent après à la respiration cellulaire connue et l'obtention de deux molécules également propres à l'être humain, la noradrénaline et l'adrénaline, intrinsèquement complémentaires de l'isoprénaline.
PCT/ES2007/000262 2006-04-28 2007-04-30 Composition à base d'isoprénaline, de noradrénaline et d'adrénaline WO2007125147A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL200601025 2006-04-28
CL1025-2006 2006-04-28

Publications (1)

Publication Number Publication Date
WO2007125147A1 true WO2007125147A1 (fr) 2007-11-08

Family

ID=38655097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2007/000262 WO2007125147A1 (fr) 2006-04-28 2007-04-30 Composition à base d'isoprénaline, de noradrénaline et d'adrénaline

Country Status (1)

Country Link
WO (1) WO2007125147A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082931A1 (fr) * 2000-04-27 2001-11-08 Sure Medical, Inc. Therapie a base d'une combinaison de (+) naloxone et d'epinephrine
US6486206B1 (en) * 1997-09-29 2002-11-26 Cprx Inc. Mechanical and pharmacologic therapies to treat cardiac arrest
WO2004093914A1 (fr) * 2003-03-28 2004-11-04 Tedor Pharma, Inc. Formulations destinees au traitement de troubles pulmonaires, reunissant un bronchodilatateur, un vasoconstricteur et un corticosteroide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486206B1 (en) * 1997-09-29 2002-11-26 Cprx Inc. Mechanical and pharmacologic therapies to treat cardiac arrest
WO2001082931A1 (fr) * 2000-04-27 2001-11-08 Sure Medical, Inc. Therapie a base d'une combinaison de (+) naloxone et d'epinephrine
WO2004093914A1 (fr) * 2003-03-28 2004-11-04 Tedor Pharma, Inc. Formulations destinees au traitement de troubles pulmonaires, reunissant un bronchodilatateur, un vasoconstricteur et un corticosteroide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] JIEHONG H. ET AL.: "Pharmacological Analysis of Isoprenaline-Adrenaline-Noradrenaline Combined Injection", accession no. STN Database accession no. (1985:56613) *
TIANJIN YIYAO, vol. 12, no. 7, 1984, pages 415 - 417 *

Similar Documents

Publication Publication Date Title
Cullen Is arsenic an aphrodisiac?: the sociochemistry of an element
US4322407A (en) Electrolyte drink
HUE035426T2 (hu) Probiotikus és prebiotikus komponenseket és ásványi sókat tartalmazó készítmények laktoferrinnel
Dowd et al. Compensatory proteome adjustments imply tissue-specific structural and metabolic reorganization following episodic hypoxia or anoxia in the epaulette shark (Hemiscyllium ocellatum)
PE20061245A1 (es) Composiciones para la transmision transmucosa oral de la metformina
Maina Bioengineering aspects in the design of gas exchangers: comparative evolutionary, morphological, functional, and molecular perspectives
KR20140136915A (ko) 세포손상 효과에 대한 보호를 제공하는 조성물
Furlan-Viebig et al. Development of a food frequency questionnaire to study diet and non-communicable diseases in adult population
CA2515407A1 (fr) Biodiversite amelioree de nutriants, d'agents pharmaceutiques, et d'autres substances bioactives par homogeneisation a resonance laser ou par modification de la forme moleculaire ou de la forme cristalline
Know Mitochondria and the future of medicine: the key to understanding disease, chronic illness, aging, and life itself
RU2472354C1 (ru) Биологически активная добавка к пище "селен-йод-эластин"
WO2007125147A1 (fr) Composition à base d'isoprénaline, de noradrénaline et d'adrénaline
JPH09183732A (ja) カリウムが支配的な非液系丸剤およびそれを用いた健康増進方法
Sircus Transdermal Magnesium Therapy: A New Modality for the Maintenance of Health
Cowley Melatonin
Voeikov Key role of stable nonequilibrium state of aqueous systems in bioenergetics
WO2007108275A1 (fr) Eau à action anticancéreuse et procédé de production
FR3024031A1 (fr) Produit de soin et shampoing, savon, creme, dentifrice, complement alimentaire et bonbon le comportant
ES2094200T3 (es) Composiciones herbicidas.
Lew Acids and bases
CN100534441C (zh) 一种水产养殖用苗种活力快速恢复剂
Gottschalk Discover the World of Microbes: Bacteria, Archaea, Viruses
KR20120119686A (ko) Ｌ-아르기닌, 비타민ｃ, 비타민 ｂ군, 비타민ａ, 비타민ｅ 및 요오드화칼륨을 주성분으로 함유하는 기능성 음료조성물
ES2961111T3 (es) Composición para complementación energética
Hussey Understanding the Heart: Surprising Insights into the Evolutionary Origins of Heart Disease—and Why It Matters

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07765845

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (THE EPO COMMUNICATIONS, FORMS 1205A DATED: 12-01-2009 AND 26-02-2009

122 Ep: pct application non-entry in european phase

Ref document number: 07765845

Country of ref document: EP

Kind code of ref document: A1